Cost-Effectiveness of Omalizumab in Chronic Idiopathic Urticaria Refractory to H1-Antihistamines in Turkey

奥马佐单抗 医学 药物经济学 耐火材料(行星科学) 儿科 成本效益 内科学 免疫球蛋白E 重症监护医学 免疫学 抗体 物理 天体生物学 风险分析(工程)
作者
Mehtap Tatar,Şaban Cem Sezen,Ayşegül Şentürk,Maria‐Magdalena Balp,Mete Şaylan,A Keskinaslan
出处
期刊:Value in Health [Elsevier BV]
卷期号:17 (7): A604-A604 被引量:2
标识
DOI:10.1016/j.jval.2014.08.2101
摘要

Omalizumab is a humanised anti-IgE recombinant monoclonal antibody approved in Turkey for treatment of chronic idiopathic (or spontaneous) urticaria (CIU) in patients resistant to standard treatment. We aimed to assess the cost-effectiveness of omalizumab compared with the standard care in the treatment of CIU patients in Turkey. A Markov model of 10 years horizon was developed to estimate costs and outcomes associated with omalizumab 300mg/every 4 weeks and standard of care for 24 weeks (SoC=licensed dose H1 antihistamines) using data from two phase III studies (ASTERIA I&II includes patients with CIU refractory to licensed dose of H1-antihistamines). The study was undertaken from a Turkish health care payer perspective. At the end of this period, omalizumab was stopped and background medication continued. Patients who have responded were retreated by the same strategy upon relapse (UAS7 ≥16 or ≥28). We used Urticaria Activity Score 7 (UAS7) to measure the outcome of the treatment and we used symptom free days (UAS7 ≤6) as the outcome measure in this cost effectiveness analysis. Resource utilization data were obtained via a Delphi panel. Unit costs were taken from the Social Security Institution’s official list. Costs and outcomes were evaluated over a lifetime and discounted at 3%. Results were presented as incremental cost/symptom free days. The incremental symptom free days with omalizumab versus SoC was 27,965 days and the incremental cost was 1,610,349 Turkish Liras for 100 patients over 10 years. The incremental cost per symptom free day was 57.59 Turkish Liras. One-way sensitivity analyses confirmed the robustness of the model results. CIU affects the quality of life of patients and is associated with direct and indirect costs to payers and society. We believe that omalizumab 300mg Q4wks is a cost-effective treatment option for patients with refractory CIU in Turkish setting.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
初初见你完成签到,获得积分10
4秒前
7秒前
思源应助淡淡月饼采纳,获得20
7秒前
dd完成签到 ,获得积分10
8秒前
Nayvue发布了新的文献求助10
12秒前
未来的幻想完成签到,获得积分10
14秒前
Kvolu29完成签到,获得积分10
15秒前
长理物电强完成签到,获得积分10
16秒前
若安在完成签到,获得积分10
17秒前
完美世界应助潘特采纳,获得10
18秒前
拼搏问薇完成签到 ,获得积分10
18秒前
单薄乐珍完成签到 ,获得积分0
21秒前
张静枝完成签到 ,获得积分10
21秒前
六步郎完成签到,获得积分10
21秒前
啊怙纲完成签到 ,获得积分10
23秒前
量子星尘发布了新的文献求助10
25秒前
scott_zip完成签到 ,获得积分10
26秒前
gxl完成签到,获得积分0
30秒前
xxx完成签到 ,获得积分10
33秒前
33秒前
努力生活的小柴完成签到,获得积分10
35秒前
37秒前
tangyong完成签到,获得积分10
39秒前
长安发布了新的文献求助10
39秒前
SucceedIn完成签到,获得积分10
40秒前
41秒前
44秒前
海洋岩土12138完成签到 ,获得积分10
45秒前
lzz完成签到 ,获得积分10
45秒前
冬雪完成签到,获得积分10
49秒前
woommoow完成签到,获得积分10
49秒前
aaatan完成签到 ,获得积分10
49秒前
lynn完成签到,获得积分10
50秒前
ABC发布了新的文献求助10
50秒前
回忆完成签到,获得积分10
51秒前
溜了溜了完成签到,获得积分10
54秒前
萧水白完成签到,获得积分10
56秒前
马桶盖盖子完成签到 ,获得积分10
56秒前
漆漆漆漆漆完成签到,获得积分10
58秒前
xzy998应助科研通管家采纳,获得10
58秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022